Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board

Comments Off on Amydis Appoints Dr. Robert N. Weinreb as First Chair of Scientific Advisory Board
Mar, 29, 2022
Amydis
Press Article

San Diego, CA, March 29, 2022: Amydis Inc., a healthcare company developing a new class of molecular retinal diagnostics and digital biomarkers to accelerate the early detection and monitoring of neurodegenerative diseases, today announced the appointment of internationally recognized clinician scientist, Robert N. Weinreb M.D. as the First Chair to the Scientific Advisory Board of […]

Amydis Announces Successful Completion of a Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer Targeting TDP43 for the Diagnosis of ALS

San Diego, December 6, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a biotechnology company developing novel ocular contrast agents (“tracers”) targeting CNS biomarkers in the eye, today announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plans for a small-molecule tracer to detect […]

Amydis Awarded $3 Million NIH Grant to Explore Novel Alpha Synuclein Retinal Tracer in Non-human Primate Models of Parkinson’s Disease and Multiple System Atrophy

San Diego, October 11, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a grant award of $3 million from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH). […]

Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer’s Diseases and other Tauopathies

San Diego, September 2, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced a new Phase 1 grant award from the National Institute of Aging at the National Institutes of Health (NIH). The grant will support […]

Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy

SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced an award of a $3 million grant from the National Institute of Aging (NIA) at National Institutes of Health (NIH). The two-year Commercialization […]

Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of a First-in-Class Retinal Tracer for the Diagnosis of Alpha-synucleinopathies

San Diego, April 26, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer biotechnology company with a broad portfolio of diagnostic candidates for detection of neurodegenerative diseases in the eye, today announced completion of pre-IND (Investigational New Drug) interaction with the U.S. Food and Drug Administration (FDA) regarding the current development plan for a […]

Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy

SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) — Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development plan for its lead […]

Amydis Awarded Michael J. Fox Foundation Grant to Accelerate Development of an Alpha-Synuclein Retinal Tracer to Diagnose Parkinson’s Disease Through the Eye

SAN DIEGO, Aug. 11, 2020 (GLOBE NEWSWIRE) — Amydis, Inc., a biotechnology company developing a new class of diagnostics to enable the early detection of neurological diseases through the retina, today announced that it has received a new grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for the Company’s pioneering retinal tracer […]

Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) — Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases, announced today that they received a Phase 2A SBIR grant award from the National Institute on Aging of the National Institutes of Health (NIH). The grant award for over $1,500,000 […]

UPDATE – Amydis Awarded Prion Disease Grant from NIH

SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) — Amydis, Inc., a privately-held pharmaceutical company developing proprietary chemistry and innovative approaches for the detection of amyloid-related diseases, announced today that they received a grant award from The National Institute of Health (NIH) to develop a novel diagnostic for prion diseases. A prion, the name derived from […]

PRESS